Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01248923 is registered in ClinicalTrials.gov with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01248923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
Not reported
Enrollment
55 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell leukemia